Open an account

Cartesian Growth Corp III

FAC · NASDAQ

$4.06−$0.32 (−7.31%)TodayMarket closed ·
Prev close $4.38

FAC analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 3 analysts

Average $13.26 (+226.6% upside)

Low
$8.08
Now
$4.06
High
$18.90

Upgrades and downgrades

The latest rating actions, newest first

FAC analyst upgrades, downgrades and rating actions
FirmDateActionRating
OppenheimerAug 25, 2026InitiatesOutperform
Cantor FitzgeraldAug 12, 2026MaintainsOverweight
Cantor FitzgeraldJun 23, 2026InitiatesOverweight

The case for and against

Updated Oct 23, 2026

Bull case

Factorial Energy is supported by unusually strong fundamental validation, with Mercedes-Benz’s 1,205 km road test, Stellantis’ 375 Wh/kg verification on 77 Ah cells, and multiple OEM relationships that collectively represent 20%+ of 2025 U.S. and European EV sales. Its outlook is strengthened by a capital-light commercialization model that reuses about 80% of standard lithium-ion equipment, reported 85%+ yields across thousands of automotive-sized cells, and a cash balance of $112.8M as of June 30, 2026, which helps fund operations into 1Q28. Near-term upside also comes from the first commercial drone battery order, a Tulip Tech partnership, and an SK On MoU, while revenue is modeled to rise from $1.5M in 2027 to $130M in 2030.

Bear case

Factorial Energy is fundamentally challenged by the gap between impressive prototype validation and unproven commercial economics, since solid-state cells still face interface resistance, dendrite risk, brittle ceramic handling, and automotive-scale manufacturing hurdles that no developer has yet solved at scale. It remains pre-revenue, with 2Q26 operating expenses of $13.0M, a net loss of $11.3M, six-month 2026 net loss of $19.9M, and an accumulated deficit of $275.5M, while going-concern language and likely future financing needs raise dilution risk despite about $117M pro forma cash. Its outlook is further weakened by concentration in lithium-metal and other battery inputs, intense competition from better-capitalized peers, and execution slippage that could push commercialization beyond late 2027 and delay the expected revenue inflection.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.